Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 04, 2026 07:00 ET | Source: Oxford Biomedica Solutions LLC

OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb

OXB to become commercial manufacturer of lentiviral vectors for Bristol Myers Squibb (BMS) CAR-T programmesMulti-year agreement with five-year initial term and option to extend Oxford, UK – 4...
December 09, 2025 07:00 ET | Source: BioNTech SE

Erste Ergebnisse aus BioNTechs und BMS’ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs

Zwischenergebnisse der globalen klinischen Phase-2-Studie bei lokal fortgeschrittenem/metastasiertem dreifach negativem Brustkrebs (triple-negative breast cancer, „TNBC“) zeigten eine ermutigende...
December 09, 2025 07:00 ET | Source: BioNTech SE

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus...
October 09, 2025 07:07 ET | Source: Research and Markets

Global and China High-Voltage Power Supply in New Energy Vehicle (BMS, BDU, Relay, Integrated Battery Box) Research Report 2025: The Shift of BMS from Centralized to Distributed Architectures

Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The "High-Voltage Power Supply in New Energy Vehicle (BMS, BDU, Relay, Integrated Battery Box) Research Report, 2025" report has been added to ...
September 18, 2025 09:00 ET | Source: Applied Systems

Applied Remains the Industry’s Leading Provider of Agency Management Systems According to Multiple Industry Lists

Chicago, IL., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Applied Systems® today announced more agencies are leveraging an Applied agency management system than any other system among the largest agencies in...
September 08, 2025 11:00 ET | Source: BioNTech SE

Erste Zwischenergebnisse aus BioNTechs und BMS‘ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig (BNT327/BMS986545) zeigen ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem kleinzelligem Lungenkrebs

Daten zur Kombination des bispezifischen PD-L1xVEGF-A-Antikörper-Kandidaten Pumitamig (BNT327/BMS986545) mit Chemotherapie zeigen weiterhin ermutigende Anti-Tumor-Aktivitäten bei Patientinnen und...
September 08, 2025 11:00 ET | Source: BioNTech SE

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”),...
June 04, 2025 12:50 ET | Source: Spherix Global Insights

As Interest Grows for New Agents to Treat Thalassemia, Hematologists Begin Early Identification of Ideal Patients for Gene Therapies Vs. New Therapeutic Options

EXTON, PA, June 04, 2025 (GLOBE NEWSWIRE) -- Despite the promise of new curative strategies for beta thalassemia, such as Casgevy (Vertex) and Zynteglo (bluebird bio), most transfusion-dependent...
June 02, 2025 06:45 ET | Source: BioNTech SE

BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt

BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen...
June 02, 2025 06:45 ET | Source: BioNTech SE

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new...